A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data.

ABSTRACT:

Background

Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the long-term safety of rucaparib in large sample population was unknown. The presented study aimed to evaluate rucaparib-associated adverse events (AEs) according to the real-world pharmacovigilance database.

Methods

Disproportionality analysis was conducted to assess the association between rucaparib and its AEs. Data were collected from the international pharmacovigilance database of US FDA Adverse Event Reporting System (FAERS) between January 2017 and June 2022. The characteristics of rucaparib-related AEs, and the onset time were further analyzed.

Results

A total of 9,296,694 AE reports w

SUBMITTER: Zhang Q 

PROVIDER: S-EPMC10416473 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature